About
Executive Summary
Clinical stage immuno-oncology company with 2 broadly applicable platform technologies
-
-
-
- CAR-CIK platform (allogeneic cytokine-induced killer (CIK) cells derived from healthy donor PBMCs)
- Autologous RNA loaded dendritic cell platform
-
-
Experienced management team with key members having worked together in the field of cell therapy for 19+ years
Fully integrated biotechnology company
-
- Operates a 20K Sq. Ft. GMP manufacturing facility with 11 clean rooms in Durham, NC
- In-house R&D and process development
Strong clinical efficacy/safety data from completed clinical trials with multiple trials on-going across several indications
Groundbreaking collaboration with Memorial Sloan Kettering extending CAR-CIK platform to solid tumors
-
- Combines cōIMMUNE® technology with proprietary CAR technologies
- Working closely with several world-class laboratories at MSK
